Supernus Pharmaceuticals Inc (SUPN) FinancialsSUPNSupernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc. (SUPN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Net product sales-Qelbree, accounting for 40.7% of total sales, equivalent to $89.24M. Other significant revenue streams include Net product sales - GOCOVRI and Collaboration revenue. Understanding this composition is critical for investors evaluating how SUPN navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Supernus Pharmaceuticals, Inc. maintains a gross margin of 73.07%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1.39%, while the net margin is -26.65%. These profitability ratios, combined with a Return on Equity (ROE) of -10.49%, provide a clear picture of how effectively SUPN converts its operational activities into shareholder value.

In the context of the broader market, SUPN competes directly with industry leaders such as RARE and PBH. With a market capitalization of $2.81B, it holds a leading position in the sector. When comparing efficiency, SUPN's gross margin of 73.07% stands against RARE's 84.11% and PBH's 49.11%. Such benchmarking helps identify whether Supernus Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Supernus reported a 32% year-over-year revenue increase to over $219 million in Q2, but faced a net loss exceeding $58 million, contrasting sharply with a net income of $22.5 million in the same period of 2025. Gross margin has decreased to 73.07% in Q2 2026, down from 79.65% in Q4 2024, indicating rising cost pressures.